vs
EXACT SCIENCES CORP（EXAS）与雷诺士国际（LII）财务数据对比。点击上方公司名可切换其他公司
雷诺士国际的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），雷诺士国际净利率更高（13.6% vs -9.8%，领先23.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs -11.2%），雷诺士国际自由现金流更多（$376.7M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.8%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
雷诺士国际是美国知名的暖通空调（HVAC）及制冷领域气候控制产品供应商，总部位于得克萨斯州理查森。公司在墨西哥萨尔蒂约、美国爱荷华州马歇尔敦、南卡罗来纳州奥兰治堡设有核心生产基地，1904年收购公司的诺里斯家族后裔约翰·W·诺里斯三世持有其9.8%的股份。
EXAS vs LII — 直观对比
营收规模更大
LII
是对方的1.4倍
$878.4M
营收增速更快
EXAS
高出34.3%
-11.2%
净利率更高
LII
高出23.4%
-9.8%
自由现金流更多
LII
多$256.3M
$120.4M
两年增速更快
EXAS
近两年复合增速
6.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $162.1M |
| 毛利率 | 70.1% | 34.7% |
| 营业利润率 | -9.4% | 18.6% |
| 净利率 | -9.8% | 13.6% |
| 营收同比 | 23.1% | -11.2% |
| 净利润同比 | 90.1% | -18.0% |
| 每股收益（稀释后） | $-0.45 | $4.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLII
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.5B | ||
| Q1 25 | $706.8M | $1.1B | ||
| Q4 24 | $713.4M | $1.3B | ||
| Q3 24 | $708.7M | $1.5B | ||
| Q2 24 | $699.3M | $1.5B | ||
| Q1 24 | $637.5M | $1.0B |
净利润EXASLII
| Q4 25 | $-86.0M | $162.1M | ||
| Q3 25 | $-19.6M | $245.8M | ||
| Q2 25 | $-1.2M | $277.6M | ||
| Q1 25 | $-101.2M | $120.3M | ||
| Q4 24 | $-864.6M | $197.7M | ||
| Q3 24 | $-38.2M | $239.0M | ||
| Q2 24 | $-15.8M | $245.9M | ||
| Q1 24 | $-110.2M | $124.3M |
毛利率EXASLII
| Q4 25 | 70.1% | 34.7% | ||
| Q3 25 | 68.6% | 32.8% | ||
| Q2 25 | 69.3% | 34.8% | ||
| Q1 25 | 70.8% | 30.6% | ||
| Q4 24 | 69.0% | 33.9% | ||
| Q3 24 | 69.4% | 32.6% | ||
| Q2 24 | 69.8% | 33.6% | ||
| Q1 24 | 70.0% | 32.5% |
营业利润率EXASLII
| Q4 25 | -9.4% | 18.6% | ||
| Q3 25 | -3.0% | 21.7% | ||
| Q2 25 | -0.3% | 23.6% | ||
| Q1 25 | -13.6% | 14.5% | ||
| Q4 24 | -122.8% | 18.2% | ||
| Q3 24 | -5.6% | 20.2% | ||
| Q2 24 | -3.8% | 22.1% | ||
| Q1 24 | -16.7% | 15.9% |
净利率EXASLII
| Q4 25 | -9.8% | 13.6% | ||
| Q3 25 | -2.3% | 17.2% | ||
| Q2 25 | -0.1% | 18.5% | ||
| Q1 25 | -14.3% | 11.2% | ||
| Q4 24 | -121.2% | 14.7% | ||
| Q3 24 | -5.4% | 16.0% | ||
| Q2 24 | -2.3% | 16.9% | ||
| Q1 24 | -17.3% | 11.9% |
每股收益（稀释后）EXASLII
| Q4 25 | $-0.45 | $4.62 | ||
| Q3 25 | $-0.10 | $6.98 | ||
| Q2 25 | $-0.01 | $7.82 | ||
| Q1 25 | $-0.54 | $3.37 | ||
| Q4 24 | $-4.69 | $5.52 | ||
| Q3 24 | $-0.21 | $6.68 | ||
| Q2 24 | $-0.09 | $6.87 | ||
| Q1 24 | $-0.60 | $3.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $34.7M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $2.4B | $1.2B |
| 总资产 | $5.9B | $4.1B |
| 负债/权益比越低杠杆越低 | — | 0.98× |
8季度趋势，按日历期对齐
现金及短期投资EXASLII
| Q4 25 | $964.7M | $34.7M | ||
| Q3 25 | $1.0B | $59.2M | ||
| Q2 25 | $858.4M | $55.1M | ||
| Q1 25 | $786.2M | $222.9M | ||
| Q4 24 | $1.0B | $422.3M | ||
| Q3 24 | $1.0B | $255.7M | ||
| Q2 24 | $946.8M | $57.8M | ||
| Q1 24 | $652.1M | $57.6M |
总债务EXASLII
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $838.2M | ||
| Q2 25 | — | $835.7M | ||
| Q1 25 | — | $834.2M | ||
| Q4 24 | — | $833.1M | ||
| Q3 24 | — | $827.6M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.2B |
股东权益EXASLII
| Q4 25 | $2.4B | $1.2B | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.5B | $900.5M | ||
| Q1 25 | $2.4B | $852.5M | ||
| Q4 24 | $2.4B | $850.2M | ||
| Q3 24 | $3.2B | $754.0M | ||
| Q2 24 | $3.2B | $577.4M | ||
| Q1 24 | $3.1B | $368.8M |
总资产EXASLII
| Q4 25 | $5.9B | $4.1B | ||
| Q3 25 | $5.9B | $3.5B | ||
| Q2 25 | $5.8B | $3.7B | ||
| Q1 25 | $5.7B | $3.5B | ||
| Q4 24 | $5.9B | $3.5B | ||
| Q3 24 | $6.7B | $3.3B | ||
| Q2 24 | $6.7B | $3.2B | ||
| Q1 24 | $6.4B | $3.0B |
负债/权益比EXASLII
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.93× | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | 1.10× | ||
| Q2 24 | — | 1.95× | ||
| Q1 24 | — | 3.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $405.9M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $376.7M |
| 自由现金流率自由现金流/营收 | 13.7% | 31.5% |
| 资本支出强度资本支出/营收 | 3.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 2.50× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $638.8M |
8季度趋势，按日历期对齐
经营现金流EXASLII
| Q4 25 | $151.7M | $405.9M | ||
| Q3 25 | $219.9M | $300.7M | ||
| Q2 25 | $89.0M | $86.8M | ||
| Q1 25 | $30.8M | $-35.8M | ||
| Q4 24 | $47.1M | $332.4M | ||
| Q3 24 | $138.7M | $452.1M | ||
| Q2 24 | $107.1M | $184.0M | ||
| Q1 24 | $-82.3M | $-22.8M |
自由现金流EXASLII
| Q4 25 | $120.4M | $376.7M | ||
| Q3 25 | $190.0M | $265.1M | ||
| Q2 25 | $46.7M | $58.3M | ||
| Q1 25 | $-365.0K | $-61.3M | ||
| Q4 24 | $10.7M | $272.2M | ||
| Q3 24 | $112.6M | $410.9M | ||
| Q2 24 | $71.2M | $151.3M | ||
| Q1 24 | $-120.0M | $-52.3M |
自由现金流率EXASLII
| Q4 25 | 13.7% | 31.5% | ||
| Q3 25 | 22.3% | 18.6% | ||
| Q2 25 | 5.8% | 3.9% | ||
| Q1 25 | -0.1% | -5.7% | ||
| Q4 24 | 1.5% | 20.2% | ||
| Q3 24 | 15.9% | 27.4% | ||
| Q2 24 | 10.2% | 10.4% | ||
| Q1 24 | -18.8% | -5.0% |
资本支出强度EXASLII
| Q4 25 | 3.6% | 2.4% | ||
| Q3 25 | 3.5% | 2.5% | ||
| Q2 25 | 5.2% | 1.9% | ||
| Q1 25 | 4.4% | 2.4% | ||
| Q4 24 | 5.1% | 4.5% | ||
| Q3 24 | 3.7% | 2.8% | ||
| Q2 24 | 5.1% | 2.3% | ||
| Q1 24 | 5.9% | 2.8% |
现金转化率EXASLII
| Q4 25 | — | 2.50× | ||
| Q3 25 | — | 1.22× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | -0.30× | ||
| Q4 24 | — | 1.68× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 0.75× | ||
| Q1 24 | — | -0.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LII
| Residential Heating And Cooling | $699.8M | 59% |
| Commercial Heating And Cooling | $495.2M | 41% |
